Ottimo Pharma Announces FDA Clearance of Investigational New Drug (IND) Application for OTP-01, a First-in-Class, Dual-Paratopic, Single-Agent, Anti-PD-1/VEGFR2 Antibody

First patient dosed and study open in leading oncology centers in US and Australia Phase I/IIA adaptive study aims to assess and optimize the dose of OTP-01 and provide safety, tolerability, and early efficacy data initially in patients known to benefit from PD-1 and/or VEGF treatment IND application data supports the potential of OTP-01 as […]

Read more

Ottimo Pharma Strengthens Board with Appointment of Roger Dansey, M.D. to its Board of Directors

Ottimo Pharma (“Ottimo”), an innovative biotech company developing one-of-a-kind PD-1/VEGFR2 dual paratopic antibodies to extend the lives of patients living with cancer, today announces the appointment of Roger Dansey, M.D., a prominent leader in oncology research and drug development, to its board of directors.

Read more

Ottimo Pharma Strengthens Leadership Team with Senior Appointments

Ottimo Pharma (“Ottimo”), an innovative biotech company developing one-of-a-kind PD1/VEGFR2 dual pathway antibodies to extend the lives of patients living with cancer, today announces the appointment of Robert Tighe as Senior Vice President of Preclinical and Translational Sciences, who will be leading Ottimo’s preclinical programs and translational strategy, and Katherine Bell-McGuinn as Senior Vice President of Clinical Development, leading Ottimo’s clinical development strategy and execution.

Read more

Ottimo Pharma Raises over $140 Million in Series A Financing

Ottimo Pharma (“Ottimo”), a private biotech company pioneering bifunctional medicines to extend the lives of people living with cancer, today announces the completion of a Series A financing round of over $140 million. The financing will accelerate the lead asset, Jankistomig, a first-in-class PD1/VEGFR2 bifunctional antibody for multiple solid tumor indications, in both IV and SC forms as well as a pipeline of follow-on bifunctional assets.

Read more

Ottimo Pharma Emerges from Stealth with Backing from Medicxi and Management Team Led by David Epstein to Accelerate Development of a Novel PD1/VEGFR2 Bi-Functional Antibody Planned to Enter the Clinic in 2025

Ottimo Pharma, a private biotech company, announces the appointment of world class industry veterans David Epstein as Chair & Chief Executive Officer, Mehdi Shahidi as Head of Development & Chief Medical Officer and James Sabry as Vice-Chair of the Board of Directors.

Read more